Patent ID: 8551530

Claim:
A method of treating acute radiation syndrome, the method comprising: identifying a subject that has experienced exposure to radiation of at least 0.3 Gray or 30 rads; and treating the said subject by administering to the subject a therapeutically effective amount of a genistein formulation, wherein the genistein formulation comprises: nanoparticulate genistein, and one or more pharmaceutically acceptable excipients forming a suspension medium, wherein the one or more pharmaceutically acceptable excipients include a water soluble polymer comprising a polyvinylpyrrolidone (PVP), wherein the nanoparticulate genistein exhibits a D (0.50) of 0.5 μm or less and no particles measure greater than 2 μm and the one or more pharmaceutically acceptable excipients are selected such that the nanoparticulate genistein is suspended within the suspension medium, and wherein the genistein formulation administered to the subject has a nanoparticulate genistein concentration selected from a concentration of between about 250 mg/mL and about 500 mg/mL, a concentration of between about 250 mg/mL and about 400 mg/mL, a concentration of between about 250 mg/mL and about 350 mg/mL, and a concentration of between about 275 mg/mL and about 325 mg/mL.